Brainomix Validates e-Lung Technology for Pulmonary Fibrosis

Brainomix has presented new studies validating its e-Lung technology for identifying progressive pulmonary fibrosis, announced in a press release. The studies were showcased at the American Thoracic Society (ATS) Conference in San Francisco, highlighting the technology's accuracy and sensitivity.

The validation comes from a collaboration with Boehringer Ingelheim, utilizing data from the INBUILD clinical trial. This partnership allowed Brainomix to conduct the first quantitative CT analysis, confirming e-Lung's reliability in identifying patients at risk of progressive pulmonary fibrosis.

The Brainomix 360 e-Lung software, which quantifies CT biomarkers in interstitial lung disease patients, has recently expanded its FDA clearance. This advancement is expected to enhance patient care by enabling clinicians to track disease progression more effectively and make timely treatment decisions.